OPKO and Entera to present oral GLP-2 analog for SBS at ESPEN 2025
OPKO Health, Inc and Entera Bio Ltd announced that their abstract “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” has been selected for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism (“ESPEN”) Congress, taking place September 13–16, 2025, in Prague, Czech Republic.
Abstract Title: First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome
Poster Viewing Date & Time: September 13, 2025, 3:30 – 4:00 p.m. local time & Welcome Reception
Poster Topic: Poster Session 1 – Liver and gastrointestinal tract
Location of Display: Forum Hall Foyer 3
The oral GLP-2 tablet program combines a proprietary long acting GLP-2 agonist developed by OPKO with Entera’s proprietary N-Tab technology for patients suffering from short bowel syndrome and additional disorders involving gastrointestinal mucosal inflammation and nutrient malabsorption. Currently, the only approved GLP-2 agonist, which is marketed under the brand GATTEX® (teduglutide), requires daily subcutaneous injections.
“Given the heterogeneity of patients with SBS and challenging compliance rates attributed to injectable GLP-2 therapy, we believe a daily tablet format may enable more personalized care of this peptide and individualize titration,” said Miranda Toledano, Entera Chief Executive Officer.
